全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用：99美元
投递稿件

查看量下载量

相关文章

更多...

英夫利昔单抗治疗IVIG无反应型川崎病的进展
Progress in the Treatment of IVIG-Resistant Kawasaki Disease with Infliximab

DOI: 10.12677/ACRP.2020.82004, PP. 18-22

Keywords: IVIG无反应型川崎病，英夫利昔单抗，综述
IVIG-Resistant Kawasaki Disease, Infliximab, Reviews

Full-Text   Cite this paper   Add to My Lib

Abstract:

川崎病(Kawasaki disease, KD)是一种以全身性血管炎为特征的急性自限性疾病，病因尚不清楚，静脉注射丙种球蛋白(intravenous immunoglobulin, IVIG)联合阿司匹林治疗可缓解川崎病的炎症反应，但仍有部分患者对治疗无反应，本文主要针对英夫利昔单抗在IVIG无反应型川崎病中的应用进行综述。
Kawasaki disease is an acute self-limited disease characterized by systemic vasculitis; etiology is unclear; intravenous immunoglobulin and aspirin therapy can alleviate the inflammation of Kawasaki disease, but there are still some patients do not respond to treatment. This review focuses on the application of infliximab in IVIG reactive Kawasaki disease.

References

[1]  Yeun, K.K. and Soo, K.D. (2016) Recent Advances in Kawasaki Disease. Yonsei Medical Journal, 57, 15.
https://doi.org/10.3349/ymj.2016.57.1.15
[2]  Campbell, A.J. and Burns, J.C. (2016) Adjunctive Therapies for Kawasaki Disease. Journal of Infection, 72, S1-S5.
https://doi.org/10.1016/j.jinf.2016.04.015
[3]  Saneeymehri, S., Baker, K. and So, T.Y. (2015) Overview of Pharmacological Treatment Options for Pediatric Patients with Refractory Kawasaki Disease. Journal of Pediatric Pharmacology & Therapeutics, 20, 163-177.
[4]  Singh, S., Vignesh, P. and Burgner, D. (2015) The Epidemiology of Kawasaki Disease: A Global Update. Archives of Disease in Childhood, 100, 1084-1088.
[5]  Wallace, C.A., French, J.W., Kahn, S.J., et al. (2000) Initial Intravenous Gammaglobulin Treatment Failure in Kawasaki Disease. Pediatrics, 105, e78.
https://doi.org/10.1542/peds.105.6.e78
[6]  Kim, T.Y., Choi, W.S., Woo, C.W., et al. (2007) Predictive Risk Factors for Coronary Artery Abnormalities in Kawasaki Disease. European Journal of Pediatrics, 166, 421-425.
https://doi.org/10.1007/s00431-006-0251-8
[7]  Kaida, Y., Kambe, T., Kishimoto, S., Koteda, Y., Suda, K., Yamamoto, R., Imai, T., Hazama, T., Takamiya, Y., Shibata, R., Nishida, H., Okuda, S. and Fukami, K. (2017) Efficacy and Safety of Plasma Exchange for Kawasaki Disease with Coronary Artery Dilatation. Renal Replacement Therapy, 3, Article No. 50.
https://doi.org/10.1186/s41100-017-0130-y
[8]  Hamada, H., Suzuki, H., Abe, J., et al. (2012) Inflammatory Cytokineprofiles during Cyclosporin Treatment for Immunoglobulin-Resistant Kawasaki Disease. Cytokine, 60, 681-685.
https://doi.org/10.1016/j.cyto.2012.08.006
[9]  Newburger, J.W., Takahashi, M. and Burns, J.C. (2016) The Present and Future: Kawasaki Disease. Journal of the American College of Cardiology, 67, 1738-1749.
https://doi.org/10.1016/j.jacc.2015.12.073
[10]  Wang, Y., Wang, W., Gong, F., et al. (2013) Evaluation of Intravenous Immunoglobulin Resistance and Coronary Artery Lesions in Relation to Th1/Th2 Cytokine Profiles in Patients with Kawasaki Disease. Arthritis & Rheumatology, 65, 805-814.
https://doi.org/10.1002/art.37815
[11]  Takahashi, K., Oharaseki, T. and Yokouchi, Y. (2014) Update on Etio and Immunopathogenesis of Kawasaki Disease. Current Opinion in Rheumatology, 26, 31-36.
https://doi.org/10.1097/BOR.0000000000000010
[12]  Agarwal, S. and Agrawal, D.K. (2016) Kawasaki Disease: Etiopathogenesis and Novel Treatment Strategies. Expert Review of Clinical Immunology, 13, 247.
https://doi.org/10.1080/1744666X.2017.1232165
[13]  Hui-Yuen, J.S., Duong, T.T. and Yeung, R.S. (2006) TNF-Alpha Is Necessary for Induction of Coronary Artery Inflammation and Aneurysm Formation in an Animal Model of Kawasaki Disease. The Journal of Immunology, 176, 6294-6301.
https://doi.org/10.4049/jimmunol.176.10.6294
[14]  Weiss, J.E., Eberhard, B.A., Chowdhury, D., et al. (2004) Infliximab as a Novel Therapy for Refractory Kawasaki Disease. Journal of Rheumatology, 31, 808-810.
[15]  Burns, J.C., Mason, W.H., Hauger, S.B., et al. (2005) Infliximab Treatment for Refractory Kawasaki Syndrome. Journal of Pediatrics, 146, 662-667.
https://doi.org/10.1016/j.jpeds.2004.12.022
[16]  Son, M.B., Gauvreau, K., Burns, J.C., et al. (2011) Infliximab for Intravenous Immunoglobulin Resistance in Kawasaki Disease: A Retrospective Study. Journal of Pediatrics, 158, 644-649.e1.
https://doi.org/10.1016/j.jpeds.2010.10.012
[17]  Youn, Y., Kim, J., Hong, Y.M., et al. (2015) Infliximab as the First Retreatment in Patients with Kawasaki Disease Resistant to Initial Intravenous Immunoglobulin. Pediatric Infectious Disease Journal, 35, 457.
https://doi.org/10.1097/INF.0000000000001039
[18]  张鹏宇, 汤楚中, 潘绪, 等. 英夫利西单抗与IVIG治疗IVIG初治无效川崎病效果比较[J]. 中国医学前沿杂志(电子版), 2018, 10(5): 66-69.
[19]  Tremoulet, A.H., Jain, S., Jaggi, P., Jimenez-Fernandez, S., Pancheri, J.M., Sun, X., et al. (2014) Infliximab for Intensification of Primary Therapy for Kawasaki Disease: A Phase 3 Randomised, Double-Blind, Placebo-Controlled Trial. The Lancet, 383, 1731-1738.
https://doi.org/10.1016/S0140-6736(13)62298-9
[20]  Nagatomo, K., Muneuchi, J., Nakashima, Y., et al. (2018) Effective Infliximab Therapy for the Early Regression of Coronary Artery Aneurysm in Kawasaki Disease. International Journal of Cardiology, 271, 317-321.
https://doi.org/10.1016/j.ijcard.2018.04.062
[21]  Nagatomo, Y., et al. (2018) Effective Infliximab Therapy for the Early Regression of Coronary Artery Aneurysm in Kawasaki Disease. International Journal of Cardiology, 271, 317-321.
[22]  Hur, G., Song, M.S., Sohn, S., Lee, H.D., Kim, G.B., Cho, H.J., et al. (2019) Infliximab Treatment for Intravenous Immunoglobulin-Resistant Kawasaki Disease: A Multicenter Study in Korea. Korean Circulation Journal, 49, 183-191.
https://doi.org/10.4070/kcj.2018.0214
[23]  Shimada, S., Matsuoka, D., Murase, T., et al. (2020) Impact of Infliximab Administration before Plasma Exchange Therapy on Patients with Kawasaki Disease. Therapeutic Apheresis and Dialysis.
https://doi.org/10.1111/1744-9987.13486
[24]  Sonoda, K., Mori, M., Hokosaki, T., et al. (2014) Infliximab plus Plasma Exchange Rescue Therapy in Kawasaki Disease. The Journal of Pediatrics, 164, 1128-1132.
https://doi.org/10.1016/j.jpeds.2014.01.020
[25]  Crandall, W.V. and Mackner, L.M. (2003) Infusion Reactions to Infliximab in Children and Adolescents: Frequency, Outcome and a Predictive Model. Alimentary Pharmacology & Therapeutics, 17, 75-84.
https://doi.org/10.1046/j.1365-2036.2003.01411.x
[26]  Chen, W.T., Huang, S.R. and Wang, J.K. (2003) Kawasaki Disease Presenting with Hepatitis and Prolonged Fever: Report of One Case. Acta Paediatrica Taiwanica, 44, 174-176.
[27]  Ierardi, E., Valle, N.D., Nacchiero, M.C., et al. (2006) Onset of Liver Damage after a Single Administration of Infliximab in a Patient with Refractory Ulcerative Colitis. Clinical Drug Investigation, 26, 673-676.
https://doi.org/10.2165/00044011-200626110-00008
[28]  Ozorio, G., McGarity, B., Bak, H., Jordan, A.S., Lau, H. and Marshall, C. (2007) Autoimmune Hepatitis Following Infliximab Therapy for Ankylosing Spondylitis. The Medical Journal of Australia, 187, 524-526.
https://doi.org/10.5694/j.1326-5377.2007.tb01396.x
[29]  Mori, M., Hara, T., Kikuchi, M., et al. (2018) Infliximab versus Intravenous Immunoglobulin for Refractory Kawasaki Disease: A Phase 3, Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter Trial. Scientific Reports, 8, Article No. 1994.
https://doi.org/10.1038/s41598-017-18387-7
[30]  Keane, J., Gershon, S., Wise, R.P., et al. (2001) Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor Alpha-Neutralizing Agent. The New England Journal of Medicine, 345, 1098-1104.
https://doi.org/10.1056/NEJMoa011110

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133